A. S. Korovkin

A. S. Korovkin

Auto-generated profile, based on publicly available information

A. S. Korovkin

Scientific Centre for Expert Evaluation of Medicinal Products

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2023 in Biological Products. Prevention, Diagnosis, Treatment
Verified
Journal Article
Open access
PDF file
AKA. S. Korovkin
A. S. Korovkin
GIG. M. Ignatyev
G. M. Ignatyev
Scientific relevance. Rotavirus disease and its consequences remain a leading vaccine-preventable cause of mortality in young children. Russia has not yet included rotavirus immunisation in the national vaccination schedule, but paediatric rotavirus vaccines are provided under several regional immunisation programmes.Aim. The authors aimed to review literature covering Russian clinical evidence of the safety and effectiveness of rotavirus vaccines and to analyse the prospects for the development of the national immunisation programme for young children using the available rotavirus vaccines and considering promising pipeline ones.Discussion. Local epidemiological studies on a range of pathogens suggest that rotaviruses are the most common cause of acute intestinal infections, especially in children under 3 years of age. Since Russia’s first rotavirus vaccine approval in 2012, the healthcare system has acquired sufficient experience with rotavirus vaccines to evaluate the safety and effectiveness of rotavirus immunisation. Long-term monitoring of the rotavirus A genotypes circulating in the country shows that currently available rotavirus vaccines cover the majority of identified rotavirus isolates. Local observational studies confirm the favourable safety profile of rotavirus vaccines and demonstrate notable effectiveness of vaccination. In the regions with high immunisation coverage, the overall morbidity has declined dramatically in vaccinated children compared to unvaccinated children; some of these regions have reported only individual hospital visits or admissions for acute intestinal infections.Conclusion. This review demonstrates that rotavirus immunisation should be included in the Russian National Immunisation Schedule.

3 October 2024 in Biological Products. Prevention, Diagnosis, Treatment
Verified
Journal Article
Open access
PDF file
AKA. S. Korovkin
A. S. Korovkin
Dmitry V. GorenkovDmitry V. Gorenkov
Dmitry V. Gorenkov
AVA. R. Volgin
A. R. Volgin
INTRODUCTION. Respiratory syncytial virus (RSV) is one of the most widespread pathogens that typically cause acute upper and lower respiratory tract infections in children and adults. Monoclonal antibody products have long been used for passive immunoprophylaxis in premature infants with bronchopulmonary dysplasia. However, vaccines have recently been licensed for the prophylactic immunisation of older adults with various risk factors for severe RSV infection (primarily, chronic cardiovascular and respiratory diseases and diabetes mellitus).AIM. This study aimed to review the current status of the development of vaccines for active immunisation against RSV infection, including the epidemiological rationale for their development, clinical trial results for licensed vaccines, recommendations for vaccination, and promising pipeline vaccines for RSV prevention.DISCUSSION. Initially hindered by the unique immunopathogenesis of RSV infection and the genetic hypervariability of RSV for a long time, attempts to develop an RSV vaccine succeeded when international researchers managed to identify a conservative neutralising antibody target capable of inducing specific immunity against RSV. This target, the RSV capsid protein stabilised in its prefusion (pre-F) conformation, can mediate viral entry into the cell following a conformational change. Several subunit vaccines based on recombinant pre-F proteins have successfully passed clinical trials and have been approved for the immunisation of older adults. In addition, one of these vaccines has been recommended for use during pregnancy to prevent RSV infection in newborns and infants. Currently, programmes are being implemented to develop novel RSV vaccines based on messenger RNA (mRNA) and non-replicating attenuated influenza vectors. This article examines and summarises the efficacy and safety parameters of two RSV vaccines approved in multiple countries around the world. Both vaccines have satisfactory safety profiles and comparable prophylactic efficacy parameters.CONCLUSIONS. Prelicensure clinical trials of novel RSV vaccines, including those being developed in the Russian Federation, should include prophylactic efficacy assessments in target patient populations. For vaccines approved by leading international regulators, clinical trials required for approval in the Russian Federation will be limited to bridging studies confirming the immunogenicity and safety of the vaccines.

28 July 2025 in Epidemiology and Vaccinal Prevention
Verified
Journal Article
Open access
PDF file
IFI. V. Fel'DBlyum
I. V. Fel'DBlyum
SGS. O. Golodnova
S. O. Golodnova
MAM. Kh. Alyeva
M. Kh. Alyeva
TRT. M. Repin
T. M. Repin
EGE. V. Gorelikova
E. V. Gorelikova
AVA. M. Vlasov
A. M. Vlasov
Relevance. The diverse serogroup composition of meningococcal pathogens circulating in different countries, the challenges in predicting serogroup prevalence, migration processes, and the active aerosol transmission mechanism of meningococcal infection necessitate the use of vaccines with the broadest possible serogroup coverage for effective prevention.Aim. To evaluate the immunological efficacy and safety of the MENVAID® vaccine for the prevention of meningococcal infections caused by serogroups A, C, Y, W, and X in the Russian Federation.Materials and Methods. The immunological efficacy and safety of the MENVAID® vaccine were assessed in a prospective, comparative, randomized, double-blind clinical trial with parallel groups involving adult volunteers aged 18 to 65 years. A total of 60 adult volunteers were randomized into two groups in a 1:1 ratio (Group I, n = 30; Group II, n = 30). The comparator vaccine was Menactra®.Study Results. For all five serogroups included in the MENVAID® vaccine, both the primary and secondary immunogenicity endpoints in adults aged 18–60 years were met in comparison to the reference product (Difference ≤10 %, GMT ratios ≥0.5, respectively), confirming that the immunogenicity of MENVAID® is non-inferior to that of the comparator vaccine, Menactra®. Moreover, MENVAID® demonstrated significantly higher GMT levels for serogroups C, Y, and W compared to the comparator vaccine. In total, 132 adverse events (AEs) were reported during the study in adults, of which 124 were related to vaccine administration and were represented by local and systemic reactions: 66 AEs were recorded in Group I participants (220 %), and 58 AEs in Group II participants (193.3 %). No statistically significant difference in the number of AEs between the groups was observed. No serious adverse events (SAEs) were reported during the study.Conclusion. The MENVAID® vaccine for the prevention of meningococcal infection caused by serogroups A, C, Y, W, and X demonstrated non-inferior efficacy and comparable safety to the comparator vaccine when administered to healthy individuals aged 18 to 60 years.

9 July 2024 in Journal Infectology
Verified
Journal Article
Open access
PDF file
AKA. S. Korovkin
A. S. Korovkin
YOYu. I. Obukhov
Yu. I. Obukhov
ESE. N. Syatchikhina
E. N. Syatchikhina
ЮОЮ. И. Обухов
Ю. И. Обухов
Various pneumococcal vaccines are available worldwide, differing in the range of serotypes coverage and type of vaccine, which determine different mechanisms of action and postvaccinal immunity. Vaccination against pneumococcal infection is recommended for both children and adults. Based on information from public sources, we analyzed recommendations for vaccination of adult patients in various countries. The information was summarized in the main blocks: the availability of government funding and vaccination programs for all persons depending on age; availability of government funding and vaccination programs for all patients with risk factors; availability of vaccination recommendations depending on age and risk factors, not funded by the state. The collected data also was analyzed according to vaccination schedules and recommended types of pneumococcal vaccines. In fact, few countries have included vaccination of adults in their preventive vaccination schedules. Pneumococcal disease vaccination in adults is primarily the prerogative of economically developed countries. Currently, there is a clear transition from mono-vaccination with the polysaccharide pneumococcal vaccine PPV23 and combined vaccination regimens with a 13or 15-valent pneumococcal conjugate vaccine with revaccination with PPV23 to monovaccination with a 20-valent pneumococcal conjugate vaccine. Taking into account the spectrum of detected pneumococcal serotypes and molecular epidemiology data available in our country, the use of PCV20 can be considered justified.

4 October 2024 in Biological Products. Prevention, Diagnosis, Treatment
Verified
Journal Article
Open access
PDF file
ASAlexander А. Soldatov
Alexander А. Soldatov
AYA. K. Yakovlev
A. K. Yakovlev
ZAZh. I. Avdeeva
Zh. I. Avdeeva
Dmitry V. GorenkovDmitry V. Gorenkov
Dmitry V. Gorenkov
AKA. S. Korovkin
A. S. Korovkin
VKV. V. Kosenko
V. V. Kosenko
INTRODUCTION. The stability assessment of biological medicinal products (BMPs) requires special approaches and regulatory requirements. Therefore, BMPs require relevant national guidelines, which are an important prerequisite for the assurance of the safe and effective use of BMPs.AIM. This study aimed to analyse national and international requirements for the stability assessment of BMPs in order to use the results to inform future development of a unified regulatory approach to estimating and confirming shelf-life periods for BMPs.DISCUSSION. Most biotechnological medicinal products (BTMPs) are proteins and are highly sensitive to environmental factors by nature. Therefore, the shelf life of a BTMP is established on the basis of real-time stability studies. Stability testing under accelerated and stress conditions is conducted to support shelf-life claims and to characterise the mechanism of protein structure degradation. The results of accelerated and stress studies can be used to select the most sensitive stability-indicating parameters and testing methods. National and international regulatory authorities have developed specialised guidelines for stability studies of BMPs of various origins, and the stability assessment approaches in the regulatory system of the Eurasian Economic Union (EAEU) are harmonised with international standards. Special considerations associated with the stability of vaccines imply that stability studies of vaccines should not only establish shelf life but also investigate stability after reconstitution and after short-term temperature excursions from the recommended cold-chain conditions.CONCLUSIONS. Special stability testing considerations for various groups of BMPs (including BTMPs and immunobiologicals) indicate the need to develop and improve the system of requirements for BMP stability assessment. This will facilitate the optimisation of the life cycle of BMPs in the Russian Federation and the other EAEU member states.

1 January 2024 in Immunologiya
Verified
Journal Article
Open access
ZAZh.I. Avdeeva
Zh.I. Avdeeva
ASAlexander А. Soldatov
Alexander А. Soldatov
NAN.A. Alpatova
N.A. Alpatova
VBV.P. Bondarev
V.P. Bondarev
VMV.D. Mosyagin
V.D. Mosyagin
VMV.A. Merkulov
V.A. Merkulov
Исследования иммуногенности терапевтических белков: методические аспекты выявления и изучения антител к лекарственному препарату